查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585816

乳癌治療藥物市場：按類型、分銷管道分類 - 全球預測 2025-2030 年

Breast Cancer Drugs Market by Type (Anti-Metabolites, Aromatase Inhibitor, CDK 4/6 Inhibitor), Distribution Channel (Ambulatory Surgical Centres, Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年乳癌治療市值為217.9億美元，預計到2024年將達到239.4億美元，複合年成長率為9.96%，到2030年將達到423.7億美元。

乳癌藥物市場包括專門用於治療和管理乳癌的藥物，例如荷爾蒙療法、化療、標靶治療和免疫治療。該市場是由全球乳癌發病率不斷上升推動的，因此需要先進的治療方法。它們的主要用途是醫療保健系統、醫院和專門的癌症治療中心，這些療法在早期和晚期癌症管理中發揮重要作用。最終用途範圍從個別患者護理到旨在改善癌症結果和生存的公共衛生努力。關鍵的市場成長要素包括生物技術和個人化醫療的進步，以及對標靶治療和免疫療法的接受度不斷提高。此外，製藥公司之間在研發方面的策略聯盟以及強大的法律規範為新參與企業和現有企業創造了獲得市場佔有率的潛在機會。然而，挑戰仍然存在，包括高昂的治療成本、嚴格的監管核准以及與癌症治療相關的副作用。此外，低收入地區也存在一些限制因素，例如在獲得先進癌症治療方面存在差異。為了克服這些挑戰，潛在的創新領域包括開發生物相似藥以降低成本、增強標靶遞送機制，例如基於奈米顆粒的遞送系統、基因標記和分析，這包括公司對精準醫學的關注。投資臨床試驗來探索新的藥物組合併利用人工智慧推進藥物發現過程也可以加速業務成長。市場仍然高度競爭和充滿活力，其特點是不斷創新和策略夥伴關係關係。公司必須優先考慮以患者為中心的方法，並促進與研究機構和醫療保健提供者的合作，以擴大產品平臺並改善治療結果，從而應對這種情況。

主要市場統計
基準年[2023] 217.9億美元
預測年份 [2024] 239.4億美元
預測年份 [2030] 423.7億美元
複合年成長率（%） 9.96%

市場動態：揭示快速發展的乳癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變乳癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 乳癌盛行率增加，女性人口老化加劇
    • 藥物技術的進步與研究的改進
    • 政府加強宣傳乳癌意識的措施和計劃
  • 市場限制因素
    • 乳癌治療藥物的副作用
  • 市場機會
    • 加強製藥公司之間的合作與夥伴關係
    • 乳癌治療新藥介紹
  • 市場挑戰
    • 藥品生產流程的嚴格規定

波特五力：駕馭乳癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對乳癌藥物市場的影響

外部宏觀環境因素在塑造乳癌治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解乳癌治療藥物市場的競爭狀況

對乳癌治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

乳癌治療市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估乳癌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪乳癌治療市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對乳癌治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 乳癌發生率增加和女性人口老化
      • 製藥技術的進步與研究的改進
      • 增加政府措施和計劃以提高人們對乳癌的認知
    • 抑制因素
      • 使用乳癌藥物的不良反應
    • 機會
      • 加強藥品製造公司之間的合作與聯盟
      • 小說介紹乳癌治療藥物
    • 任務
      • 藥品生產流程的嚴格規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章乳癌治療藥物市場：按類型

  • 代謝抑制劑
  • Aromatase抑制劑
  • CDK 4/6抑制劑
  • HER2抑制劑
  • 荷爾蒙受體
  • 有絲分裂抑制劑

第7章乳癌治療藥物市場：按分銷管道

  • 門診手術中心
  • 診所
  • 醫院
  • 線上管道
  • 零售藥房

第8章北美和南美乳癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區乳癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的乳癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • A. Menarini Industrie Farmaceutiche Riunite srl
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05264

The Breast Cancer Drugs Market was valued at USD 21.79 billion in 2023, expected to reach USD 23.94 billion in 2024, and is projected to grow at a CAGR of 9.96%, to USD 42.37 billion by 2030.

In the breast cancer drugs market, the scope encompasses a range of pharmaceuticals specifically designed for the treatment and management of breast cancer, including hormone therapy, chemotherapy, targeted therapy, and immunotherapy. This market is driven by a growing prevalence of breast cancer worldwide, necessitating advanced therapeutics. The application predominantly lies in healthcare systems, hospitals, and specialized cancer treatment centers, where these drugs play a critical role in both early and late-stage cancer management. The end-use scope varies from individual patient care to public health initiatives aimed at improving cancer outcomes and survival rates. Significant market growth factors include advancements in biotechnology and personalized medicine, increasing the acceptance of targeted therapies and immunotherapy. Moreover, strategic collaboration among pharmaceutical companies for R&D efforts and robust regulatory frameworks are creating potential opportunities for new entrants and existing firms to gain market share. However, challenges persist, such as high treatment costs, stringent regulatory approvals, and adverse side effects associated with cancer therapies. Further limitations involve disparities in access to advanced cancer treatments in low-income regions. To overcome these challenges, potential areas for innovation include the development of biosimilars to reduce costs, enhancing targeted delivery mechanisms like nanoparticle-based delivery systems, and focusing on precision medicine through genetic markers and profiling. Business growth could be accelerated by investing in clinical trials that explore new drug combinations and leveraging artificial intelligence to advance drug discovery processes. The nature of the market remains highly competitive and dynamic, characterized by continuous innovations and strategic partnerships. Companies must navigate this landscape by prioritizing patient-centric approaches and fostering collaborations with research institutions and healthcare providers to expand their product pipelines and improve therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 21.79 billion
Estimated Year [2024] USD 23.94 billion
Forecast Year [2030] USD 42.37 billion
CAGR (%) 9.96%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Drugs Market

The Breast Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of breast cancer and rising geriatric population of women
    • Improved advancements and research in drug technologies
    • Growth in government initiatives and programs to spread awareness about breast cancer
  • Market Restraints
    • Adverse effects caused by the use of breast cancer drugs
  • Market Opportunities
    • Increasingly collaboration and partnership among drug manufacturing companies
    • Introduction of novel breast cancer drugs
  • Market Challenges
    • Stringent regulation on drug manufacturing process

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Drugs Market

A detailed market share analysis in the Breast Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Drugs Market

A strategic analysis of the Breast Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Industrie Farmaceutiche Riunite s.r.l., Amgen Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Anti-Metabolites, Aromatase Inhibitor, CDK 4/6 Inhibitor, HER2 Inhibitor, Hormonal Receptor, and Mitotic Inhibitor.
  • Based on Distribution Channel, market is studied across Ambulatory Surgical Centres, Clinics, Hospitals, Online Channels, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of breast cancer and rising geriatric population of women
      • 5.1.1.2. Improved advancements and research in drug technologies
      • 5.1.1.3. Growth in government initiatives and programs to spread awareness about breast cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects caused by the use of breast cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasingly collaboration and partnership among drug manufacturing companies
      • 5.1.3.2. Introduction of novel breast cancer drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulation on drug manufacturing process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Anti-Metabolites
  • 6.3. Aromatase Inhibitor
  • 6.4. CDK 4/6 Inhibitor
  • 6.5. HER2 Inhibitor
  • 6.6. Hormonal Receptor
  • 6.7. Mitotic Inhibitor

7. Breast Cancer Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centres
  • 7.3. Clinics
  • 7.4. Hospitals
  • 7.5. Online Channels
  • 7.6. Retail Pharmacies

8. Americas Breast Cancer Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Breast Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A. Menarini Industrie Farmaceutiche Riunite s.r.l.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bristol Myers Squibb Company
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Fresenius SE & Co. KGaA.
  • 8. Gilead Sciences, Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Sanofi S.A.
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BREAST CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BREAST CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. BREAST CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 107. BREAST CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023